American Association of Individual Investors5d
Why Gain Therapeutics, Inc.’s (GANX) Stock Is Up 13.74%
Gain Therapeutics, Inc.’s GANX share price has surged by 13.74%, which has investors questioning if this is right time to sell.
Pharmaceutical Technology23d
Why pharma is still far from a treatment for galactosemia
Current paediatric standard-of-care for galactosemia is a lactose-free diet. Image credit: Shutterstock / Photoongraphy. Nearly three months after an experimental treatment for classic galactosemia ...
clinicaltrialsarena23d
Why pharma is still far from a treatment for galactosemia
Current paediatric standard-of-care for galactosemia is a galactose-free diet. Image credit: Shutterstock / Photoongraphy. Nearly three months after an experimental treatment for classic galactosemia ...